WO2011094671A3 - N-terminally conjugated polypeptides for targeted therapy and diagnosis - Google Patents

N-terminally conjugated polypeptides for targeted therapy and diagnosis Download PDF

Info

Publication number
WO2011094671A3
WO2011094671A3 PCT/US2011/023140 US2011023140W WO2011094671A3 WO 2011094671 A3 WO2011094671 A3 WO 2011094671A3 US 2011023140 W US2011023140 W US 2011023140W WO 2011094671 A3 WO2011094671 A3 WO 2011094671A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide moiety
agent
polypeptide
conjugates
moiety
Prior art date
Application number
PCT/US2011/023140
Other languages
French (fr)
Other versions
WO2011094671A2 (en
Inventor
Ahmad Safavy
Original Assignee
The Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Uab Research Foundation filed Critical The Uab Research Foundation
Publication of WO2011094671A2 publication Critical patent/WO2011094671A2/en
Publication of WO2011094671A3 publication Critical patent/WO2011094671A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/50—Lipopolysaccharides; LPS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides polypeptide conjugates comprising a polypeptide moiety and an agent, wherein the polypeptide moiety is linked to the agent through the -amino group of the polypeptide moiety. The present disclosure also provides methods for the manufacture of polypeptide conjugates comprising a polypeptide moiety and an agent, wherein the polypeptide moiety is linked to the agent through the -amino group of the polypeptide moiety. The methods disclosed provide for the selective attachment of the agent to the polypeptide moiety. Furthermore, the method of attachment utilizes mild conditions to link the polypeptide moiety and the agent, thereby maintaining the overall molecular structure of the polypeptide moiety so that is biological activity and/or binding activity is maintained. Such conjugates have many uses, for example in targeting specific cell types, treating disease, preventing disease, and diagnosing disease.
PCT/US2011/023140 2010-01-29 2011-01-31 N-terminally conjugated polypeptides for targeted therapy and diagnosis WO2011094671A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29978310P 2010-01-29 2010-01-29
US61/299,783 2010-01-29

Publications (2)

Publication Number Publication Date
WO2011094671A2 WO2011094671A2 (en) 2011-08-04
WO2011094671A3 true WO2011094671A3 (en) 2011-12-22

Family

ID=44320190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/023140 WO2011094671A2 (en) 2010-01-29 2011-01-31 N-terminally conjugated polypeptides for targeted therapy and diagnosis

Country Status (1)

Country Link
WO (1) WO2011094671A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304630A (en) * 2012-03-07 2013-09-18 中国科学院大连化学物理研究所 GPCR active polypeptide in scorpion venom of Buthus martensii Karsch, and extracting separation and application thereof

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602006020710D1 (en) 2005-04-22 2011-04-28 Fred Hutchinson Cancer Res Foundation FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR THE INTRAOPERATIVE VIEW OF CANCER
JP2011520914A (en) 2008-05-15 2011-07-21 トランスモレキュラー， インコーポレイテッド Treatment of metastatic tumor
CN102844044B (en) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 Catilan polypeptide and conjugate and application thereof
JP2013532126A (en) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター Chlorotoxin variants, conjugates, and methods of using them
CN104080335B (en) 2011-09-01 2017-06-09 钱向平 Some chemical entities, composition and method
RU2015126651A (en) 2012-12-10 2017-01-16 Фред Хатчинсон Кэнсер Рисёрч Сентер SCREENING METHODS
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2022144560A1 (en) 2020-12-30 2022-07-07 Vascular Venture Korlátolt Felelősségű Társaság Chlorotoxin derivatives and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129188A1 (en) * 2001-10-22 2003-07-10 The Scripps Research Institute Integrin targeting compounds
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
US20080152660A1 (en) * 2005-03-03 2008-06-26 Bradshaw Curt W Anti-Angiogenic Compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129188A1 (en) * 2001-10-22 2003-07-10 The Scripps Research Institute Integrin targeting compounds
US20050069551A1 (en) * 2002-03-08 2005-03-31 Emory University Cytotoxic compound-protein conjugates as suppressors of tumor growth and angiogenesis
US20080152660A1 (en) * 2005-03-03 2008-06-26 Bradshaw Curt W Anti-Angiogenic Compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304630A (en) * 2012-03-07 2013-09-18 中国科学院大连化学物理研究所 GPCR active polypeptide in scorpion venom of Buthus martensii Karsch, and extracting separation and application thereof
CN103304630B (en) * 2012-03-07 2014-09-17 中国科学院大连化学物理研究所 GPCR active polypeptide in scorpion venom of Buthus martensii Karsch, and extracting separation and application thereof

Also Published As

Publication number Publication date
WO2011094671A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2011094671A3 (en) N-terminally conjugated polypeptides for targeted therapy and diagnosis
CY1122816T1 (en) TARGETED BINDING AGENTS AGAINST B7-H1
WO2010107256A3 (en) Method for preparing a site-specific physiologically active polypeptide conjugate
EP4303236A3 (en) Cytotoxicity-inducing therapeutic agent
EA201170158A1 (en) AGENTS CONNECTING WITH NOTCH1 RECEPTOR AND METHODS OF THEIR APPLICATION
HK1121530A1 (en) Assays for detection of antibodies to lysosomal enzymes
WO2008063511A3 (en) Methods for treating pompe disease
EP2860192A3 (en) Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38
IN2012MN02262A (en)
BR112013030432A2 (en) method for preparing a target conjugate peptide for a recombinant lysosomal enzyme, method for preparing a molecule for enzyme replacement therapy, conjugate, method for treating an individual suffering from a lysosomal storage disease, method for treating an individual suffering from a lysosomal storage, method for treating a patient suffering from pompe disease, fabry disease, and gaucher disease, mps i, mps ii, tay sachs, sandhoff, alpha-mannosidosis, and wohlman, dna sequence, and sequence of amino acids
WO2010081001A3 (en) Recurrent gene fusions in cancer
WO2006050058A3 (en) Methods of detection and therapy of inflamed tissues using immune modulation
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
AR062268A1 (en) BINDING AGENTS DIRECTED TO PDGFR-ALFA AND ITS USES
MX2013007067A (en) Anti-il-18 antibodies and their uses.
WO2008070672A3 (en) Compositions and methods to treat cancer with cupredoxins and cpg rich dna
WO2007064727A3 (en) Penetrabodies: receptor-mediated targeted delivery of functionally-active human antibody fragments into cytosol for the treatment of chronic infections and diseases
WO2007139815A3 (en) Imaging and therapeutic method using progenitor cells
WO2008151005A3 (en) Compositions and methods for tissue repair
WO2010025321A3 (en) Method for treating multiple sclerosis patients with anti-il2r antibodies
WO2007100920A3 (en) Diagnosis and treatment of prostate cancer
EA025738B9 (en) Method of conjugating a water soluble polymer to a therapeutic protein (embodiments) and resulted modified protein (embodiments)
WO2012138694A3 (en) Compositions comprising saccharide binding moieties and methods for targeted therapy
BR112012022337A2 (en) composition and method of preparation and use of effective amount
GB0620255D0 (en) Antibody and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11737808

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11737808

Country of ref document: EP

Kind code of ref document: A2